Literature DB >> 17033807

Predictive risk factors for coronary artery abnormalities in Kawasaki disease.

Taeyeun Kim1, Wooksun Choi, Chan-Wook Woo, Byungmin Choi, Junghwa Lee, Kwangchul Lee, Changsung Son, Joowon Lee.   

Abstract

Clinical characteristics to predict the development of coronary artery abnormalities (CAA) in Kawasaki disease (KD) were assessed by reviewing medical records of patients diagnosed with KD at Korea University Medical Center from March 2001 to February 2005. Of the 285 patients diagnosed with KD, 19 developed CAA (6.7%). Compared with the CAA(-) group, the CAA(+) group had a longer duration of fever after intravenous gamma-globulin (IVGG) injection (2.4+/-2.9 vs. 1.5+/-1.2 days, p=0.008) and higher C-reactive protein (CRP)(12.3+/-7.8 vs. 8.7+/-7.1 mg/dL, p=0.038). In particular, the CAA(+) group tended to have more than 7 days of fever before IVGG and more than 3 days of fever after IVGG (26.3 vs. 5.3%, p<0.001; 26.3 vs. 6.4%, p=0.002). When the IVGG responsiveness was defined by the presence of defervescence within 3 days after IVGG, IVGG-non-responders showed a higher incidence of CAA (22.7 vs. 5.3%, p=0.002). Non-responders had a longer duration of fever after IVGG (5.5+/-1.9 vs. 1.2+/-0.6 days, p<0.001) and a significantly increased CRP, AST, ALT and total bilirubin. Multivariate regression analysis for CAA showed that the only factor significantly associated with the development of CAA was total fever that lasted for longer than 8 days (OR=4.052, 95% CI=1.151-14.263, p=0.0293). Conclusively, the most important predictor of CAA in KD is total duration of fever longer than 8 days. Early identification of IVGG non-responders and active therapeutic intervention for fever in KD cases might decrease the incidence of CAA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033807     DOI: 10.1007/s00431-006-0251-8

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  25 in total

1.  A multicenter collaborative study on the risk factors of cardiac sequelae due to Kawasaki disease: a one-year follow-up study.

Authors:  I Oki; S Tanihara; T Ojima; Y Nakamura; H Yanagawa
Journal:  Acta Paediatr       Date:  2000-12       Impact factor: 2.299

2.  Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset.

Authors:  M Fukunishi; M Kikkawa; K Hamana; T Onodera; K Matsuzaki; Y Matsumoto; J Hara
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

3.  Coronary risk factors in Kawasaki disease treated with additional gammaglobulin.

Authors:  M Miura; H Ohki; T Tsuchihashi; H Yamagishi; Y Katada; K Yamada; Y Yamashita; A Sugaya; O Komiyama; H Shiro
Journal:  Arch Dis Child       Date:  2004-08       Impact factor: 3.791

4.  Risk factors associated with the need for additional intravenous gamma-globulin therapy for Kawasaki disease.

Authors:  Hiromi Muta; Masahiro Ishii; Jun Furui; Yosikazu Nakamura; Toyojiro Matsuishi
Journal:  Acta Paediatr       Date:  2006-02       Impact factor: 2.299

5.  Coronary artery dimensions may be misclassified as normal in Kawasaki disease.

Authors:  A de Zorzi; S D Colan; K Gauvreau; A L Baker; R P Sundel; J W Newburger
Journal:  J Pediatr       Date:  1998-08       Impact factor: 4.406

6.  Coronary diameter in normal infants, children and patients with Kawasaki disease.

Authors:  Shunji Kurotobi; Toshisaburo Nagai; Nobuhiro Kawakami; Tetsuya Sano
Journal:  Pediatr Int       Date:  2002-02       Impact factor: 1.524

7.  Brain natriuretic peptide as a hormonal marker of ventricular diastolic dysfunction in children with Kawasaki disease.

Authors:  S Kurotobi; N Kawakami; K Shimizu; H Aoki; S Nasuno; K Takahashi; S Kogaki; K Ozono
Journal:  Pediatr Cardiol       Date:  2005 Jul-Aug       Impact factor: 1.655

8.  Regression of aneurysms in Kawasaki disease: a pathological study.

Authors:  Y Sasaguri; H Kato
Journal:  J Pediatr       Date:  1982-02       Impact factor: 4.406

9.  Pathological features of coronary arteries in children with Kawasaki disease in which coronary arterial aneurysm was absent at autopsy. Quantitative analysis.

Authors:  T Fujiwara; H Fujiwara; H Nakano
Journal:  Circulation       Date:  1988-08       Impact factor: 29.690

Review 10.  Advances in Kawasaki disease.

Authors:  Stanford T Shulman; Anne H Rowley
Journal:  Eur J Pediatr       Date:  2004-06       Impact factor: 3.860

View more
  30 in total

1.  Evaluation of echogenicity of the heart in Kawasaki disease.

Authors:  Hazumu Nagata; Kenichiro Yamamura; Kiyoshi Uike; Yasutaka Nakashima; Yuichiro Hirata; Eiji Morihana; Yumi Mizuno; Shiro Ishikawa; Toshiro Hara
Journal:  Eur J Pediatr       Date:  2014-08       Impact factor: 3.183

2.  The Trilogy of SARS-CoV-2 in Pediatrics (Part 2): Multisystem Inflammatory Syndrome in Children.

Authors:  Van L Tran; Sarah Parsons; Andrew Nuibe
Journal:  J Pediatr Pharmacol Ther       Date:  2021-05-19

3.  Complete and incomplete Kawasaki disease: two sides of the same coin.

Authors:  Cedric Manlhiot; Erin Christie; Brian W McCrindle; Hans Rosenberg; Nita Chahal; Rae S M Yeung
Journal:  Eur J Pediatr       Date:  2011-12-03       Impact factor: 3.183

4.  Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience.

Authors:  Lorna Stemberger Maric; Ivica Knezovic; Neven Papic; Branko Mise; Srdan Roglic; Leo Markovinovic; Goran Tesovic
Journal:  Rheumatol Int       Date:  2014-11-28       Impact factor: 2.631

5.  Incomplete clinical manifestation as a risk factor for coronary artery abnormalities in Kawasaki disease: a meta-analysis.

Authors:  Kee-Soo Ha; GiYoung Jang; JungHwa Lee; KwangChul Lee; YoungSook Hong; ChangSung Son; JooWon Lee
Journal:  Eur J Pediatr       Date:  2012-11-16       Impact factor: 3.183

6.  Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.

Authors:  Manju Mamtani; Tomoyo Matsubara; Chisato Shimizu; Susumu Furukawa; Teiji Akagi; Yoshihiro Onouchi; Akira Hata; Akihiro Fujino; Weijing He; Sunil K Ahuja; Jane C Burns
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

7.  Incomplete Kawasaki disease in patients younger than 1 year of age: a possible inherent risk factor.

Authors:  Yunku Yeo; TaeYeon Kim; KeeSoo Ha; GiYoung Jang; JungHwa Lee; KwangChul Lee; ChangSung Son; JooWon Lee
Journal:  Eur J Pediatr       Date:  2008-05-14       Impact factor: 3.183

8.  Associated symptoms in the ten days before diagnosis of Kawasaki disease.

Authors:  Annette L Baker; Minmin Lu; L LuAnn Minich; Andrew M Atz; Gloria L Klein; Rosalind Korsin; Linda Lambert; Jennifer S Li; Wilbert Mason; Elizabeth Radojewski; Victoria L Vetter; Jane W Newburger
Journal:  J Pediatr       Date:  2008-11-28       Impact factor: 4.406

9.  The prognostic role of abnormal liver function in IVIG unresponsiveness in Kawasaki disease: a meta-analysis.

Authors:  Ling Liu; Wei Yin; Ruigeng Wang; Dongming Sun; Xuelian He; Yan Ding
Journal:  Inflamm Res       Date:  2015-12-08       Impact factor: 4.575

10.  Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome.

Authors:  Donato Rigante; Piero Valentini; Daniela Rizzo; Andrea Leo; Gabriella De Rosa; Roberta Onesimo; Alessia De Nisco; Donatella Francesca Angelone; Adele Compagnone; Angelica Bibiana Delogu
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.